Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer is a phase 3 interventional study registered as NCT07222566, led by Pfizer, and recruiting on the registry. Official title: An interventional phase 3, double-blind, randomised study to evaluate efficacy and safety of PF-08634404 in combination with chemotherapy versus pembrolizumab in combination with chemotherapy in adult participants with locally advanced or metastatic non-small cell lung cancer. Planned enrolment is 1410 participants (estimated). The study started in 2026-01-06 and primary completion is expected in 2029-02-27. No results have been posted on ClinicalTrials.gov.